Abstract
Cholangiocarcinoma is an uncommon cancer that arises from the intrahepatic and extrahepatic portions of the biliary system. Since it is often difficult to diagnose and frequently presents at a late stage, it carries a bad prognosis. Despite the recent advancement of multidisciplinary approaches, surgical resection remains the only potential curative treatment. We describe the current perioperative and surgical management of cholangiocarcinoma at our institution with recent supportive evidence.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Alvaro D, Cannizzaro R, Labianca R, et al. Cholangiocarcinoma: a position paper by the Italian Society of Gastroenterology (SIGE), the Italian Association of Hospital Gastroenterology (AIGO), the Italian Association of Medical Oncology (AIOM) and the Italian Association of Oncological Radiotherapy (AIRO). Dig Liver Dis. 2010;42:831–8.
Burak K, Angulo P, Pasha TM, et al. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol. 2004;99:523–6.
Broome U, Olsson R, Loof L, et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut. 1996;38:610–5.
Hakamada K, Sasaki M, Endoh M, et al. Late development of bile duct cancer after sphincteroplasty: a ten-to twenty-two year follow up study. Surgery. 1997;1215:488–92.
Roukounakis NE, Kuhn JA, McCarty TM. Association of an abnormal pancreaticobiliary junction with biliary tract cancers. Proc (Bayl Univ Med Cent). 2000;13:11–3.
Shaib YH, El-Serag HB, Davila JA, et al. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case control study. Gastroenterology. 2005;128:620–6.
Alberts SR, Gores GJ, Kim GP, et al. Treatment options for hepatobiliary and pancreatic cancer. Mayo Clin Proc. 2007;82:628–37.
Burke EC, Jarnagin WR, Hochwald SN, et al. Hilar cholangiocarcinoma: patterns of spread, the importance of hepatic resection for curative operation, and a pre-surgical clinical staging system. Ann Surg. 1998;228:385–94.
Bismuth H, Corlette MB. Intrahepatic cholangioenteric anastomosis in carcinoma of the hilum of the liver. Surg Gynecol Obstet. 1975;140:170–8.
Bergquist A, Ekbom A, Olsson R, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol. 2002;36:321–7.
Cleary SP, Knox J, Dawson L. Carcinoma of the biliary tract. In: Blanke CD, Rodel C, Talamonti MS, editors. Gastrointestinal oncology: a practical guide. Berlin: Springer; 2010. p. 251–99.
Stain SC, Guthrie CR, Yellin AE, Donovan AJ. Choledochal cyst in the adult. Ann Surg. 1995;222:128–33.
Khan SA, Davidson BR, Goldin R, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut. 2002;51 Suppl 6:vi1–9.
Bridgewater J, Galle PR, Khan SA, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014;60:1268–89.
Kondo N, Murakami Y, Uemura K, et al. Elevated perioperative serum CA19-9 levels are independent predictors of poor survival in patients with resectable cholangiocarcinoma. J Surg Oncol. 2014;110:422–9.
Chapman R, Fevery J, Kalloo A, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology. 2010;51:660–78.
Cleary SP, Dawson LA, Knox JJ, Gallinger S. Cancer of the gallbladder and extrahepatic bile ducts. Curr Probl Surg. 2007;44:396–482.
Rosen CB, Heimbach JK, Gores GJ. Liver transplantation for cholangiocarcinoma. Transpl Int. 2010;23:692–7.
Sio TT, Martenson JA, Haddock MG, et al. Outcome of transplant-fallout patients with unresectable cholangiocarcinoma. Am J Clin Oncol. 2014. [Epub ahead of print].
Jarnagin WR, Fong Y, DeMatteo RP, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg. 2001;234:507–17.
Baron TH. Expandable metal stents for the treatment of cancerous obstruction of the gastrointestinal tract. N Engl J Med. 2001;344:1681–7.
Eckel F, Brunner T, Jelic S. On behalf of the ESMO Guidelines Working Group Biliary cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v65–9.
Kondo S, Takada T, Miyazaki M, et al. Guidelines for the management of biliary tract and ampullary carcinomas: surgical treatment. J Hepato-Biliary-Pancreat Surg. 2008;15:41–54.
Clary B, Jarnigan W, Pitt H, et al. Hilar cholangiocarcinoma. J Gastrointest Surg. 2004;8:298–302.
Valle J, Wasan H, Palmer D, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273–81.
Primrose JN, Fox RP, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20(5):663–73.
Edeline J, Benabdelghani M, Bertaut A, et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. J Clin Oncol. 2019;37(8):658–67.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Latchana, N., Cleary, S., Moulton, Ca.E. (2020). Cholangiocarcinoma. In: Wright, F., Escallon, J., Cukier, M., Tsang, M., Hameed, U. (eds) Surgical Oncology Manual. Springer, Cham. https://doi.org/10.1007/978-3-030-48363-0_5
Download citation
DOI: https://doi.org/10.1007/978-3-030-48363-0_5
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-48362-3
Online ISBN: 978-3-030-48363-0
eBook Packages: MedicineMedicine (R0)